Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients
Oslo, Norway, 4 January 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces immune activation data in the first four patients treated with ONCOS-102 followed by the checkpoint inhibitor (CPI) pembrolizumab (KEYTRUDA®) in patients with advanced melanoma whose disease has progressed after prior CPI treatment. This is the first time ONCOS-102 has been used therapeutically in melanoma patients, and also the first time the virus has been administered to CPI refractory patients. In this Phase I open